Our Take
Roche executed the hard part (replacing $21B in eroding blockbusters with $26B in new growth drivers) and now faces the harder part: entering obesity and IBD markets already crowded with cheaper, faster entrants.
Why it matters
Pharma pipelines typically survive on one or two blockbusters for 15+ years. Roche's forced reinvention is now a case study in how to build portfolio resilience when patent cliffs accelerate. Practitioners in biopharma M&A and clinical strategy should watch whether Roche's combination approach (CT-388 + petrelintide in obesity) or novel mechanism (afimkibart in IBD) can justify late-market entry against entrenched competitors.
Do this week
Biotech dealmakers: model Roche's two acquisition archetypes (large late-stage, small platform buys) and test whether your pipeline de-risking aligns with their $10B annual M&A capacity before approaching them.
How Roche replaced $21B in oncology losses in five years
Roche's three blockbuster oncology drugs, Herceptin, Avastin, and Rituxan, generated roughly $21 billion in peak annual sales before biosimilars arrived. By 2019, the company modeled a CHF 9.6 billion ($11.8 billion) revenue gap between 2018 and 2023. That timeline compressed: the gap was crossed by 2021, with Avastin shedding 32% of sales year-on-year, Herceptin 19%, and Rituxan 21% (per company filings). Rather than shrink, Roche grew.
Five new growth drivers filled the crater. Ocrevus (multiple sclerosis) reached CHF 7.01 billion ($8.6 billion) in 2025, becoming Roche's largest seller. Hemlibra (hemophilia A) hit CHF 4.8 billion ($5.9 billion), up 11% year-on-year. Vabysmo (retinal disease) launched in early 2022 and became one of the fastest-growing products. Phesgo and Xolair completed the portfolio. Combined, these five generated CHF 21.4 billion ($26.4 billion) in 2025, up CHF 3.2 billion ($3.9 billion) from 2024. All extended Roche's internal antibody and bispecific antibody platforms into new indications.
But Roche did not stop consolidating. Since 2023, the company has deployed over $15 billion in upfront capital across dealmaking in obesity, inflammatory bowel disease (IBD), metabolic dysfunction-associated steatohepatitis (MASH), allogeneic cell therapy, and next-generation breast cancer oncology.
Roche's obesity bet is audacious timing, not audacious science
Roche's lead obesity asset, CT-388, is a once-weekly dual GLP-1/GIP agonist acquired via the $2.7 billion Carmot Therapeutics deal in late 2023. In January 2026, phase 2 data showed 22.5% placebo-adjusted weight loss at 48 weeks without reaching a plateau (per company announcement). Two phase 3 trials started in Q1 2026. This positions Roche 3-4 years behind Eli Lilly's Zepbound and Novo Nordisk's Wegovy, both of which have established physician infrastructure, payer relationships, and patient uptake.
Roche's answer is combination therapy. The company acquired Zealand Pharma's petrelintide (amylin analog) for CHF 1.65 billion upfront to complement CT-388 by reducing nausea and preserving lean mass, with a combination study planned for H1 2026. The bet is that by the time CT-388 reaches market, combination regimens will be standard of care. This is not a novel mechanism; it is a timing gamble on tolerability becoming the differentiation vector.
The IBD play carries similar execution risk. Roche paid $7.1 billion upfront to Telavant for afimkibart, an anti-TL1A antibody targeting both inflammation and fibrosis in ulcerative colitis and Crohn's disease. Phase 3 trials are underway with regulatory filing expected in 2027. However, TL1A has become crowded: Merck, Sanofi/Teva, AbbVie, Spyre, and Boehringer Ingelheim are all pursuing the target. In June 2026, Merck announced positive phase 3 results with tulisokibart in ulcerative colitis, beating Roche to the milestone. Roche will likely enter as a second or third competitor, materially altering the commercial calculus around the $7.1 billion price tag.
On cell therapy, the $1.5 billion Poseida acquisition gives Roche an allogeneic CAR-T platform it lacked. Poseida's lead candidate showed a 91% overall response rate in phase 1 data in multiple myeloma (per company data). Allogeneic platforms enable off-the-shelf manufacturing, potentially lower costs, and faster access than autologous CAR-T. This is credible differentiation in a market shifting toward manufacturability.
What Roche's playbook reveals about pharma portfolio construction
Roche's dealmaking strategy reflects two clear archetypes. The first is large-scale acquisitions of late-stage or phase 3-ready assets where clinical risk is substantially de-risked: Telavant ($7.1B for afimkibart), Carmot ($2.7B for CT-388 and obesity candidates), and 89bio ($2.4B upfront for pegozafermin in MASH). The second is smaller, targeted platform buys: Poseida ($1.5B for allogeneic CAR-T), Regor ($850M for next-generation CDK inhibitors), and the Zealand collaboration ($1.65B for petrelintide). Together, they signal that Roche is willing to pay premium prices for assets that extend internal platforms or fill therapeutic gaps, but only when clinical data exists to support the bet.
The execution risk is real. Roche faces first-entrant disadvantage in obesity and fast followers in IBD. The company's internal pipeline rationalization in early 2024 (eight discontinuations across neurology, oncology, and hematology) shows it can also kill programs that lack differentiation. Success depends on whether combination therapy and novel fibrosis targeting can justify late market entry against cheaper, entrenched competitors who have already captured physician mindshare and payer contracts. For practitioners evaluating similar portfolio bets, Roche's playbook is neither bold nor reckless; it is a deliberate choice to pay for de-risking rather than to build from early stage and wait.